E-DRUG: Independent Drug and Healthcare Newsletter for May 2019
-----------------------------------------------------------------------------------
Newsletter, May 2019
Independent Drug & Healthcare Newsletter from the non-profit journal Prescrire International
View the contents
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
Like what you see?
Subscribe to Prescrire International
In Prescrire's Spotlight this month
--------------------------------------------------------------------------------
FEATURED REVIEW
Drug-induced retinal disorders
Retinal damage can cause different types of visual disturbances, of varying severity. Many drugs can provoke retinal disorders. What are the underlying mechanisms? Which drugs are responsible?
Read more
--------------------------------------------------------------------------------
FREE DOWNLOAD
In the May issue of Prescrire International: Dupilumab (Dupixent°) in adults with atopic dermatitis
Dupilumab (Dupixent°), a monoclonal antibody, is an option for very troublesome eczema after failure of ciclosporin. Full text available for free download.
Read more
--------------------------------------------------------------------------------
SUBSCRIBE NOW
Subscribe today for full access to top-quality content from Prescrire International
Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries).
Subscribe now
--------------------------------------------------------------------------------
Vaccine hesitancy: understand it better, to provide better support
Rather than considering people reluctant to vaccinate as irresponsible, it is better to try to restore confidence by improving public knowledge, identifying the barriers and seeking ways to overcome them.
Read more
--------------------------------------------------------------------------------
Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow
A study conducted by the independent French medical journal Prescrire shows a reduction of only around 26% in the number of patients in France exposed to at least one Alzheimer's disease drug between 2012 and 2017. In approximately 3 out of 4 newly exposed patients, treatment lasted for more than 6 months, despite the proven harms.
Read more
--------------------------------------------------------------------------------
Methylphenidate (Ritalin°) as a means of controlling classroom behaviour
Too many children are overdiagnosed with attention deficit hyperactivity disorder (ADHD) simply because they are the youngest in the class and so tend to be more easily distracted and disruptive.
Read more
--------------------------------------------------------------------------------
ADVANCING HEALTHCARE POLICY
The use of "big data" in the authorisation and supervision of health products must rely on facts, trustworthy evidence and transparency
In its response to the public consultation on big data organised by the HMA-EMA Joint Big Data Taskforce, Prescrire considers that regulation on the authorisation and supervision of health products cannot be based on hope and promises but needs to rely on facts, trustworthy evidence and transparency.
Read more
-------------------------------------------------------------------------------
COMING SOON
Enjoy these features, and more, in our upcoming issues
Ruxolitinib in myelofibrosis * Methylphenidate during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects * Ginkgo biloba: seizures * Oral anticoagulants in atrial fibrillation * Talking to patients about risks: strategies for better communication...
Subscribe now
Share this with a friend or colleague: Forward this email
Prescrire International <international@prescrire.org>